Pharmaceutical formulation containing gelling agent
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
1. A controlled release oral solid dosage form comprising:
(i) a first population of particles comprising an opioid analgesic, and
(ii) a second population of particles comprising a gelling agent,
wherein the particles of the first population are free from the gelling agent,
the particles of the second population are free from the opioid analgesic, and
when exposed to from about 0.5 ml to about 10 ml of water, the dosage form forms a gel that cannot be drawn into an insulin syringe without picking up pockets of air.
2. The controlled release oral solid dosage form of claim 1 , wherein the gelling agent is polyethylene oxide.
3. The controlled release oral solid dosage form of claim 2 , wherein the particles of the second population comprise an acrylic polymer.
4. The controlled release oral solid dosage form of claim 3 , wherein the acrylic polymer is an ammonio methacrylate copolymer.
5. The controlled release oral solid dosage form of claim 1 , wherein the particles of the second population comprise polyvinylpyrrolidone.
6. The controlled release oral solid dosage form of claim 1 , wherein the dosage form provides a therapeutic effect for about 12 hours.
7. The controlled release oral solid dosage form of claim 1 , wherein the particles of the first population and the particles of the second population are contained in a pharmaceutically acceptable capsule.
8. The controlled release oral solid dosage form of claim 1 , wherein the particles of the first population are about 0.5 mm to about 2 mm in diameter.
9. The controlled release oral solid dosage form of claim 1 , wherein the particles of the second population are about 0.5 mm to about 2 mm in diameter.
10. The controlled release oral solid dosage form of claim 1 , wherein the particles of the first population and the particles of the second population have a diameter of about 0.5 mm.
11. The controlled release oral solid dosage form of claim 1 , wherein the particles of the first population comprise an acrylic polymer.
12. The controlled release oral solid dosage form of claim 11 , wherein the acrylic polymer is an ammonio methacrylate copolymer.
13. The controlled release oral solid dosage form of claim 6 , wherein the particles of the first population are controlled release beads.
14. The controlled release oral solid dosage form of claim 1 , wherein dosage form provides a therapeutic effect for about 24 hours.
15. The controlled release oral solid dosage form of claim 1 , wherein the dosage form is a tablet.
16. A controlled release oral solid dosage form comprising:
(i) a first population of particles comprising an opioid analgesic, and
(ii) a second population of particles comprising a gelling agent,
wherein the particles of the first population are free from the gelling agent,
the particles of the second population are free from the opioid analgesic, and
when exposed to from about 0.5 ml to about 10 ml of water, the dosage form forms a gel that cannot be injected from an insulin syringe.
17. The controlled release oral solid dosage form of claim 16 , wherein the opioid analgesic comprises hydrocodone or a pharmaceutically acceptable salt thereof.
18. The controlled release oral solid dosage form of claim 16 , wherein the opioid analgesic comprises oxycodone or a pharmaceutically acceptable salt thereof.
19. The controlled release oral solid dosage form of claim 16 , wherein the gelling agent is polyethylene oxide.
20. The controlled release dosage form of claim 16 , wherein the dosage form is a tablet.